Related Experiment Video
Updated: May 6, 2026
08:51
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
Published on: March 1, 2013
15.6K
Poly(amidoamine) dendrimer complexes as a platform for gene delivery.
Dzmitry Shcharbin1, Antos Shakhbazau, Maria Bryszewska
1Institute of Biophysics and Cell Engineering of NASB , Minsk , Belarus.
Expert Opinion on Drug Delivery
|October 31, 2013
Summary
Poly(amidoamine) dendrimers show promise as non-viral gene carriers, offering high transfection efficiency with low immunogenicity. Further research is needed to address toxicity concerns for human gene therapy applications.
Area of Science:
- Biotechnology
- Nanomedicine
- Gene Therapy
Background:
- Gene therapy offers effective treatment for diseases like cancer and genetic disorders.
- Viral and non-viral systems are crucial for nucleic acid delivery in gene therapy.
- Non-viral gene delivery systems are increasingly utilized in clinical trials.
Purpose of the Study:
- To review advancements in poly(amidoamine) dendrimers for gene delivery.
- To compare dendrimers with viral vectors and other non-viral systems.
- To discuss the potential and challenges of dendrimers in gene therapy.
Main Methods:
- Review of recent literature on poly(amidoamine) dendrimers.
- Analysis of in vitro and in vivo gene delivery data.
- Comparative assessment of dendrimers versus viral vectors, liposomes, and linear polymers.
Main Results:
- Dendrimers exhibit high transfection efficiency and are non-immunogenic.
- Dendrimers present advantages over viral systems, lacking their characteristic drawbacks.
- Modifications enhance dendrimer transfection efficiency and reduce cytotoxicity.
Conclusions:
- Dendrimers are promising non-viral gene carriers with significant potential.
- Toxicity of dendrimers in vitro and in vivo requires careful consideration.
- Further research is essential before widespread clinical application in human gene therapy.
